Corinne Johnson
Stock Analyst at Goldman Sachs
(4.45)
# 1,154
Out of 4,988 analysts
231
Total ratings
52.9%
Success rate
13.6%
Average return
Main Sectors:
Stocks Rated by Corinne Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HRMY Harmony Biosciences Holdings | Reiterated: Hold | $33 → $37 | $42.02 | -11.95% | 23 | Jul 16, 2026 | |
| SNDX Syndax Pharmaceuticals | Reiterated: Buy | $34 | $17.62 | +92.96% | 8 | Jul 14, 2026 | |
| AMLX Amylyx Pharmaceuticals | Reiterated: Buy | $20 → $23 | $32.41 | -29.03% | 19 | Jun 18, 2026 | |
| HALO Halozyme Therapeutics | Reiterated: Sell | $56 → $57 | $112.45 | -49.31% | 18 | Jun 14, 2026 | |
| RYTM Rhythm Pharmaceuticals | Reiterated: Buy | $158 → $159 | $97.71 | +62.73% | 31 | Jun 14, 2026 | |
| IDYA IDEAYA Biosciences | Reiterated: Hold | $35 → $36 | $38.41 | -6.27% | 11 | Jun 3, 2026 | |
| TGTX TG Therapeutics | Reiterated: Hold | $41 | $56.87 | -27.91% | 21 | Jun 3, 2026 | |
| NBIX Neurocrine Biosciences | Initiated Coverage: Buy | $182 → $213 | $146.23 | +45.66% | 3 | Jun 2, 2026 | |
| ORIC ORIC Pharmaceuticals | Reiterated: Buy | $15 | $12.79 | +17.28% | 2 | Jun 2, 2026 | |
| BHVN Biohaven | Reiterated: Buy | $27 → $25 | $13.62 | +83.55% | 3 | May 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $2.5 | $3.25 | -23.08% | 8 | Apr 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $28 → $32 | $36.95 | -13.40% | 6 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $38 → $41 | $39.77 | +3.09% | 29 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $102 → $101 | $35.00 | +188.57% | 2 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $1 | $1.30 | -23.08% | 17 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $56 → $82 | $74.62 | +9.89% | 6 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Sell | $32 | $62.91 | -49.18% | 1 | Dec 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $28.90 | n/a | 3 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.76 | n/a | 4 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | n/a | $1.91 | n/a | 5 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $6.79 | n/a | 6 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $5.50 | n/a | 4 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $22 | $0.6653 | n/a | 1 | Sep 14, 2021 |
Harmony Biosciences Holdings
Jul 16, 2026
Reiterated: Hold
Price Target: $33 → $37
Current: $42.02
Upside: -11.95%
Syndax Pharmaceuticals
Jul 14, 2026
Reiterated: Buy
Price Target: $34
Current: $17.62
Upside: +92.96%
Amylyx Pharmaceuticals
Jun 18, 2026
Reiterated: Buy
Price Target: $20 → $23
Current: $32.41
Upside: -29.03%
Halozyme Therapeutics
Jun 14, 2026
Reiterated: Sell
Price Target: $56 → $57
Current: $112.45
Upside: -49.31%
Rhythm Pharmaceuticals
Jun 14, 2026
Reiterated: Buy
Price Target: $158 → $159
Current: $97.71
Upside: +62.73%
IDEAYA Biosciences
Jun 3, 2026
Reiterated: Hold
Price Target: $35 → $36
Current: $38.41
Upside: -6.27%
TG Therapeutics
Jun 3, 2026
Reiterated: Hold
Price Target: $41
Current: $56.87
Upside: -27.91%
Neurocrine Biosciences
Jun 2, 2026
Initiated Coverage: Buy
Price Target: $182 → $213
Current: $146.23
Upside: +45.66%
ORIC Pharmaceuticals
Jun 2, 2026
Reiterated: Buy
Price Target: $15
Current: $12.79
Upside: +17.28%
Biohaven
May 28, 2026
Reiterated: Buy
Price Target: $27 → $25
Current: $13.62
Upside: +83.55%
Apr 24, 2026
Upgraded: Hold
Price Target: $2.5
Current: $3.25
Upside: -23.08%
Apr 15, 2026
Rated: Hold
Price Target: $28 → $32
Current: $36.95
Upside: -13.40%
Apr 15, 2026
Reiterated: Buy
Price Target: $38 → $41
Current: $39.77
Upside: +3.09%
Mar 16, 2026
Reiterated: Buy
Price Target: $102 → $101
Current: $35.00
Upside: +188.57%
Feb 25, 2026
Reiterated: Sell
Price Target: $1
Current: $1.30
Upside: -23.08%
Jan 12, 2026
Reiterated: Buy
Price Target: $56 → $82
Current: $74.62
Upside: +9.89%
Dec 4, 2025
Initiated Coverage: Sell
Price Target: $32
Current: $62.91
Upside: -49.18%
Jul 18, 2025
Reiterated: Buy
Price Target: n/a
Current: $28.90
Upside: n/a
Jul 31, 2024
Reiterated: Buy
Price Target: n/a
Current: $3.76
Upside: n/a
Jul 24, 2024
Reiterated: Sell
Price Target: n/a
Current: $1.91
Upside: n/a
Jun 18, 2024
Reiterated: Hold
Price Target: n/a
Current: $6.79
Upside: n/a
Aug 7, 2023
Reiterated: Buy
Price Target: n/a
Current: $5.50
Upside: n/a
Sep 14, 2021
Downgraded: Hold
Price Target: $22
Current: $0.6653
Upside: n/a